Technology

Google Ad

Melinta Therapeutics focusing on the development and commercialization of novel antibiotics to treat serious bacterial infections presented multiple presentations at the European Congress of Clinical Microbiology Infectious Diseases (ECCMID).

Medical Technology

"Since innovation fuels the medical device sector's ongoing quest for better ways to treat and diagnose medical conditions, when coupled with patient life expectancy increasing and aging populations globally, the medical device sector should continue growing at a positive rate in the future."

Melinta Therapeutics MLNT announced that researchers are scheduled to present multiple scientific data presentations with data from its antibiotic portfolio at this year's 29 [th] European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), April 13-16 in Amsterdam, Netherlands.

"The body of data presented at ECCMID represents an important step in the global fight against antimicrobial resistance and delivering anti-infective solutions to patients," said Sue Cammarata, M.D., chief medical officer of Melinta.

"We are pleased that these data will be shared within the infectious disease community to further elucidate the value and utility of these anti-infective agents."

Analysts are eager to see the reception of MLNT's research as the world looks to treat and understand next level infectitious disease with the increasing inefficiency of many traditional antibiotics and medical devices.

Melinta

Fourth Quarter and Full-Year Results - March 13 2019

In the fourth quarter, sales of commercial products increased 32% compared to the third quarter of 2018, driven by strong Vabomere® (meropenem and vaborbactam) and Orbactiv® (oritavancin) performance

  • Delivered full-year 2018 revenues of $96.4 million, including $46.6 million in net product sales
  • Melinta ended the year with $81.8 million of cash and cash equivalents

Portfolio Updates

Vabomere received European Commission approval in November 2018 for the following indications in adult patients:

  • -- Complicated intra-abdominal infections (cIAI)
  • -- Complicated urinary tract infections (cUTI)
  • -- Hospital-acquired pneumonia including ventilator associated pneumonia (HAP/VAP)
  • -- Bacteraemia that occurs in association with any of these infections
  • -- Infections due to aerobic Gram-negative organisms where treatment options are limited

Reported positive top-line results from the Phase III trial of Baxdela® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) in October 2018 Began preparation of supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for Baxdela in CABP, which is expected to be filed in the second quarter of 2019

Entered into a commercial agreement with Menarini Group to commercialize Vabomere, Orbactiv and Minocin® (minocycline) for injection in 68 countries outside of the U.S. in October 2018

Business Highlights

  • John H. Johnson named permanent chief executive officer
  • Closed the initial $75 million disbursement under the previously announced $135 million convertible loan facility from Vatera Healthcare Partners, LLC on February 22, 2019
  • Implementation of operating cost reduction initiatives expected to deliver significant cost savings in 2019
  • Strengthened Board of Directors and senior leadership team through new appointments adding beneficial experience and expertise to Melinta
  • Effected a one-for-five reverse stock split of the Company's common stock on February 22, 2019

Recent active Healthcare companies in the medical device industry include:

About Melinta Therapeutics, Inc.

MLNT is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta’s lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

From The TradersCommunity Research Desk

Log in to comment
Discuss this article in the forums (0 replies).